Key result
Aggressive immunosuppression and mechanical circulatory support fail to prevent death in fulminant lupus-associated giant cell myocarditis.
Why the study?
Giant cell myocarditis is a rare and often fatal subtype of myocarditis, with limited reports of association with systemic lupus erythematosus.
Case Report (n=1)
No
Giant cell myocarditis should be considered in young patients with systemic lupus erythematosus presenting with rapidly progressing heart failure, as it requires early biopsy and aggressive immunosuppression but carries a poor prognosis.
Answers are grounded in this paper and cite their sources.
Death despite therapy in this SLE-giant cell myocarditis case cautions against optimism; extends sparse literature but leaves optimal strategies open.
Background: Giant cell myocarditis (GCM) is a rare, and often fatal subtype of myocarditis, with limited reports of association with systemic lupus erythematosus (SLE). Purpose: We are first to report a unique case of an 18-year-old patient presenting with biventricular heart failure and newly-onset SLE, ultimately diagnosed with GCM. Analysis/Results: The patient had a 6-month prodrome of fatigue, fever, and malaise, followed by acute decompensation. Echocardiography showed a severely reduced left ventricular ejection fraction (5%). Serology confirmed SLE, endomyocardial biopsy identified multinucleated giant cells, confirming GCM. Despite immediate initiation of extracorporeal membrane oxygenation (ECMO) and aggressive immunosuppressive therapy (methylprednisolone, antithymocyte globulin, cyclosporine), cardiac function did not recover. The patient received a biventricular assist device (BiVAD) as intermediate-term bridge-to-transplant. However, significant complications occurred in the form of multiorgan failure, thromboembolism, and hemodynamic deterioration, ultimately leading to death before transplantation was possible. Conclusions: This case underscores the importance of differentiating lupus myocarditis from GCM, given the dramatically different prognosis and treatment strategies. Early differential diagnosis via biopsy is essential, particularly in young patients with rapidly progressing cardiac decline and concurrent autoimmune serologies. Aggressive immunosuppression remains the cornerstone of treatment, attempting to reduce myocardial damage and the resulting need for transplantation. Clinicians should maintain suspicion of GCM in lupus patients with cardiac compromise to initiate timely interventions.
No takes yet. Share an insight, caveat, or question.
Harling et al. (2026) conducted a case report in Giant cell myocarditis and systemic lupus erythematosus (n=1). Aggressive immunosuppressive therapy and mechanical circulatory support was evaluated on Clinical outcome. Despite aggressive immunosuppressive therapy and mechanical circulatory support, the 18-year-old patient with giant cell myocarditis and systemic lupus erythematosus died from multiorgan failure.
Synapse has enriched 10 related papers. Consider them for comparative context: